SRPT 13F Hedge Fund and Asset Management Owners

Data based on most recent fiscal year report
Market Cap	4.69 Billion	Shares Outstanding	64.63 Million	Avg Volume	3.299 Million
1-Yr BETA vs S&P TR		Current Ratio	13.91	Quick Ratio	12.96

AVI Biopharma, Inc.

Q3 2019	All Institutions	Hedge Funds ¹
To trade SRPT now:
Filers who had this stock in their top 10:	6	6 (0.63%)
13F Filers holding this stock:	322	46 (4.81%)
Aggregate 13F shares on 09/30/2019:	70.538 Million	12.718 Million
Aggregate 13F shares on 06/30/2019:	70.597 Million	10.422 Million
Percent change:	-0.08%	22.03%
Funds creating new positions:	70	15
Funds Adding to an existing position:	119	20
Funds closing out their position:	90	28
Funds reducing their position:	99	9
¹ hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Sarepta Therapeutics Inc Chart by YCharts

Yahoo! Finance

finviz

Check out our reporting and analysis

Protagonist Therapeutics insiders bought as shares crashed 45%. The next day PTGX rebounded 73%.
via whalewisdomalpha 12/04/2019
Is Bill Oberndorf the best stock picker in the U.S.? The low profile fund manager ties Abdiel Capital for best risk-adjusted 13F performance.
via whalewisdomalpha 12/02/2019
Broadcom’s Cheap Stock Is Catching Investors’ Attention 12/02/2019
The January Effect and insider trading. Smart money is buying these oversold stocks into year end.
via whalewisdomalpha 11/25/2019
Fiserv Was Among the Most Sought After Stocks in the Third Quarter 11/25/2019
Stadium Capital's Q3 return was 33.01% -- #1 among hedge funds*. Tiger Legatus, Baker Bros and ValueAct also had big quarters.
via whalewisdomalpha 11/20/2019
Berkshire Hathaway’s Surprising New Addition to its Portfolio 11/18/2019
Prospect for a Return to Growth Pulls Investors into Nvidia 11/12/2019

Funds Holding SRPT (via 13F filings)

Quarter to view: Refresh Download CSV Download Excel (.xlsx) Download TSV

Click for Additional Filters

Market Value:

Ranking:

% of portfolio

Refresh

*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

25 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

34.3 Thousand total shares from 7 transactions

Current/Former Insiders

Insider Name	Type	Last Reported Shares Held	Last Reported Date	Filings in past year
HOWTON DAVID T EVP, GENERAL COUNSEL	Officer	25,171	2019-11-22	4
CASEY MICHAEL D		0	2019-11-20	0
BONNEY MICHAEL W		0	2019-11-20	2
CIAMBRONE WILLIAM EVP	Officer	0	2019-11-18	2
BEHRENS M KATHLEEN	Director	62,500	2019-09-18	2
BARRY RICHARD	Director	3,187,065	2019-09-12	5
MAHATME SANDESH EVP, CFO & CBO	Officer	42,191	2019-08-21	7
INGRAM DOUGLAS S PRESIDENT & CEO	Officer Director	432,197	2019-08-12	1
CHASE ANTHONY R	Director	0	2019-08-08	0
GRAY MARY ANN	Director	7,355	2019-07-19	3
KAYE EDWARD M. MD CEO	Officer Director	0	2019-06-18	0
CUMBO ALEXANDER	Director	0	2019-06-11	3
PRICE BEN GIL		0	2019-06-06	0
HENNEY CHRISTOPHER S	Director	0	2019-05-29	0
WIGZELL HANS LENNART RUDOLF	Director	11,717	2019-05-23	2
O'NEILL GILMORE NEIL EVP, R&D & CMO	Officer	7,370	2019-05-23	2
NICAISE CLAUDE	Director	7,051	2019-03-04	1
O'NEILL GILMORE NEIL EVP, R&D & CMO O'NEILL GILMORE NEIL EVP, R&D & CMO	Officer	0	2019-03-04	2
JACOBSEN MICHAEL A VP FINANCE AND CAO	Officer	0	2019-02-08	0
APHALE JAYANT SEE REMARKS	Officer	0	2018-09-27	0
RUFF SHAMIM SVP, CHIEF REGULATORY AFFAIRS	Officer	31,936	2018-05-22	0
HAYWOOD GEORGE WEAVER	Director	0	2018-05-09	0
BASI GURIQBAL S. SVP, CHIEF SCIENTIFIC OFFICER	Officer	0	2018-03-05	0
KRESS JEAN-PAUL EVP PRES INT'L & GLOBAL HD GTO	Officer	0	2017-07-03	0
STEHMAN-BREEN CATHERINE SVP, CHIEF MEDICAL OFFICER	Officer	0	2017-04-03	0
WOOD JOAN VP, HUMAN RESOURCES	Officer	14,926	2016-09-20	0
SHREWSBURY STEPHEN B CMO; SENIOR VP CLINICAL DEV.	Officer	0	2016-03-10	0
GOOLSBEE WILLIAM ALDEN	Director	8,166	2016-02-29	0
TIMMINS ALAN P	Director	0	2015-07-30	0
HODGMAN JOHN	Director	6,333	2015-02-27	0
CHRISTOPHER NISHAN GARABEDIAN PRESIDENT AND CEO	Officer Director	29,552	2015-02-27	0
KRIEG ARTHUR M SVP, CHIEF SCIENTIFIC OFFICER	Officer	0	2014-01-13	0
MARTIGNETTI ANTHONY	SEE REMARKS	0	2013-06-04	0
BOYLE J DAVID II SENIOR VP AND CFO	Officer	0	2012-01-04	0
TOSHAV BRACHA EPHRAT SR VP & GENERAL COUNSEL	Officer	0	2011-08-31	0
MILE MELINDA G CONTROLLER AND PAO	Officer	0	2011-08-31	0
LINSLEY PETER S SVP & CHIEF SCIENTIFIC OFFICER	Officer	0	2011-05-16	0
IVERSEN PATRICK L SR VP OF RESEARCH & DEVLOPMENT	Officer	0	2010-08-23	0
WELLER DWIGHT D SR. VP CHEMISTRY & MFG.	Officer	0	2010-08-23	0
MEDEIROS PAUL SVP BUSINESS DEVELOPMENT	Officer	0	2010-08-23	0
JOHNSON GRAHAM SR VP PRECLINICAL DEV & RSRCH	Officer	0	2010-08-23	0
HUDSON LESLIE FORMER CEO	Officer FORMER CEO	384,559	2010-07-30	0
EASTBOURNE CAPITAL MANAGEMENT LLC/CA	10% Owner	No longer subject to file	2010-05-10	0
ROCKALL EMERGING MARKETS MASTER FUND LTD O'DRISCOLL CONOR EGAN CON MELDRUM ASSET MANAGEMENT, LLC	MAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBER	2,935,696	2010-03-16	0
HAYWOOD GEORGE WEAVER HAYWOOD CHERYL	MAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBER	8,329,126	2010-03-16	0
KOLE RYSZARD SVP/DISCOVERY RESEARCH	Officer	1,862,926	2010-02-09	0
BLACK BEAR OFFSHORE MASTER FUND LP	10% Owner	7,971,542	2009-09-28	0
FORREST K MICHAEL OUTSIDE DIRECTOR	Officer Director	15,000	2009-05-19	0
FARA JOHN W PHD	Director DIRECTOR	500	2008-05-20	0
OHANLEY PETER D SR. VICE PRESIDENT	Officer	0	2008-02-28	0
WEBBER MARK MILES CFO	Officer	15,446	2008-02-02	0

Insider Transactions Last 60 Days

Reporting Owners	Transaction Date	Transaction Code	Shares	Share Price	Acquired or Disposed	Shares Owned Following Transaction	Combined shares owned after filing	Direct/Indirect Ownership	10b-5
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	5,590		d	0	25,171.00	direct
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	8,580		d	18,579	25,171.00	direct	yes
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	F	2,804	$107.02	d	25,171	25,171.00	direct
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	52	$13.71	a	14,485	25,171.00	direct
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	S	3,753	$105.00	d	14,950	25,171.00	direct	yes
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	4,025	$13.71	a	28,413	25,171.00	direct	yes
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	52		d	18	25,171.00	direct
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	4,025		d	1,858	25,171.00	direct	yes
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	7,900	$23.85	a	27,975	25,171.00	direct
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	2,440	$13.71	a	14,433	25,171.00	direct
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	S	18,290	$105.00	d	18,703	25,171.00	direct	yes
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	5,685	$13.71	a	24,388	25,171.00	direct	yes
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	7,900		d	5,118	25,171.00	direct
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	2,440		d	2,470	25,171.00	direct
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	5,685		d	1,280	25,171.00	direct	yes
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	5,590	$13.90	a	20,075	25,171.00	direct
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	S	2,957	$105.00	d	11,993	25,171.00	direct	yes
HOWTON DAVID T - Officer EVP, GENERAL COUNSEL	2019-11-22	M	8,580	$13.90	a	36,993	25,171.00	direct	yes
CIAMBRONE WILLIAM - Officer EVP	2019-11-18	A	80,000		a	80,000	0.00	direct

Click here to report any possible errors with this stock listing.

Sarepta Therapeutics Inc (SRPT)

Check out our reporting and analysis

Funds Holding SRPT (via 13F filings)

Filter by:

Active Schedule 13D and 13G filings

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

Open Market Sells (S)

Exercise Derivative Conversion (M)

Current/Former Insiders

Insider Transactions Last 60 Days

Elevate your investments

Sarepta Therapeutics Inc (SRPT)

Check out our reporting and analysis

Funds Holding SRPT (via 13F filings)

Filter by:

Active Schedule 13D and 13G filings

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

Open Market Sells (S)

Exercise Derivative Conversion (M)

Current/Former Insiders

Insider Transactions Last 60 Days

Report an error

Elevate your investments